529
Views
4
CrossRef citations to date
0
Altmetric
Point of View

Dissecting monoclonal antibody mega-deals

&
Pages 172-178 | Received 02 Oct 2008, Accepted 15 Dec 2008, Published online: 01 Mar 2009

References

  • Bogdan B, Villiger R. Valuation in Life Sciences. A Practical Guide 2008; Second Edition Springer Verlag 171 - 173
  • DiMasi J, Grabowski H. The Cost of Biopharmaceutical R&D: Is Biotech Different?. Manage Decis Econ 2007; 28:469 - 479
  • Reichert J. Success and failure: Clinical trials of protein therapeutics 2005; Conference on plant-made pharmaceuticals
  • Reichert J, Rosensweig C, Faden L, Dewitz M. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 1078
  • Reichert J. Biopharmaceutical Approvals in the US Increase. RAJ Pharma 2004;
  • Schneider, Kalinke. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985 - 990
  • Longman R. Why Investor's Don't Like Biotech Alliances?. IN VIVO Blog 2008; March

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.